Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of Blood, Blood Forming Organs and Immunologic DisordersDRG 808-major-hematological-and-immunological-diagnoses-except-sickle-cell-crisis-and-coagulation-disorders-with-mcc
    Ask Trek AI about this page

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    DRG 808 includes major hematological and immunological conditions, excluding sickle cell crisis and coagulation disorders, when a Major Complication or Comorbidity is present and influencing resource needs. Proper classification matters for inpatient reimbursement because the Major Complication or Comorbidity status increases payment to reflect higher acuity, more intensive therapies, and longer hospital stays.

    Customize your policy alerts

    Sign up for drg 808 policy alerts

    Get alerted when payer policies referencing 808 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 808 Overview

    DRG 808 covers major hematological and immunological diagnoses excluding sickle cell crisis and coagulation disorders when a Major Complication or Comorbidity is present, typically involving complex medical management such as severe cytopenias, bone marrow failure, or aggressive autoimmune disorders. This group captures high-acuity inpatient stays with resource-intensive diagnostics, transfusions, immunomodulatory therapies, and prolonged monitoring. It matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates payment relative to lower-severity groups to reflect increased resource use and length of stay. Accurate coding of primary diagnosis and accompanying Major Complication or Comorbidity drives correct case assignment and reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute intervention trials evaluating novel immunomodulatory or hematopoietic therapies in patients hospitalized with severe autoimmune cytopenias or fulminant hemophagocytic syndromes. These studies enroll inpatients with life‑threatening hematological manifestations (for example, severe aplastic anemia, autoimmune hemolytic anemia with hemodynamic instability, or macrophage activation syndrome) to assess rapid‑onset agents, dosing strategies, and safety during the index hospitalization. Results inform acute management protocols, resource utilization (ICU stays, transfusion needs), and short‑term outcomes that directly affect inpatient reimbursement and DRG cost weights.
    • Comparative effectiveness research comparing transfusion strategies, immunosuppressive regimens, or stem cell transplant timing in subgroups of major hematologic/immunologic diagnoses excluding sickle cell and coagulation disorders. These pragmatic studies typically enroll heterogeneous inpatient and early post‑discharge populations (e.g., newly diagnosed severe aplastic anemia or refractory autoimmune cytopenias) to compare real‑world effectiveness, adverse events, and readmission rates between standard care options. Findings help providers select therapies that balance clinical benefit and complication risk and help payers predict downstream costs, length of stay, and likelihood of high‑cost MCCs impacting DRG payments.
    • Longitudinal outcomes and health‑services research examining post‑discharge morbidity, readmissions, quality of life, and long‑term costs among patients hospitalized with major hematologic or immunologic diagnoses. These cohort studies follow patients after episodes complicated by MCCs to quantify late complications (infections, chronic cytopenias, graft failure after transplant), outpatient resource needs, and drivers of recurrent hospital utilization. This research is relevant for designing care pathways, discharge planning, and case management interventions that can reduce readmissions and inform reimbursement models and bundled payment approaches for this high‑acuity DRG.

    Related Codes

    799-SPLENIC-PROCEDURES-WITH-MCC

    Splenic Procedures with MCC: Inpatient Reimbursement Overview

    800-SPLENIC-PROCEDURES-WITH-CC

    Splenic Procedures with CC: Inpatient Reimbursement Overview

    801-SPLENIC-PROCEDURES-WITHOUT-CC-MCC

    Splenic Procedures without CC/MCC: Inpatient Reimbursement Overview

    802-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITH-MCC

    Other O.R. Procedures of the Blood and Blood Forming Organs with MCC: Inpatient Reimbursement Overview

    803-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITH-CC

    Other O.R. Procedures of the Blood and Blood Forming Organs with CC: Inpatient Reimbursement Overview

    804-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITHOUT-CC-MCC

    Other O.R. Procedures of the Blood and Blood Forming Organs without CC/MCC: Inpatient Reimbursement Overview

    809-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITH-CC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    810-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITHOUT-CC-MCC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    811-RED-BLOOD-CELL-DISORDERS-WITH-MCC

    Red Blood Cell Disorders with MCC: Inpatient Reimbursement Overview

    812-RED-BLOOD-CELL-DISORDERS-WITHOUT-MCC

    Red Blood Cell Disorders without MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 14

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.